Episode Details
Back to Episodes
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
Published 1 month ago
Description
In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical in a deal worth up to $745 million, the FDA grants full approval to Filspari as the first and only approved treatment for focal segmental glomerulosclerosis, and Pharmaceutical Executive speaks with Deepak Prakash of Identiv on how RFID and real-time tracking are building operational visibility in clinical trials.